NCT04569032 2026-02-18
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Phase 2 Completed
Seagen Inc.
University of Nebraska
National Institutes of Health Clinical Center (CC)
Eisai Inc.
M.D. Anderson Cancer Center